Modification Form for Permit BIO-RRI-0026

Permit Holder: Caroline Schild Poulter

Approved Personnel
(Please stroke out any personnel to be removed)

Dawn Bryce

Additional Personnel
(Please list additional personnel here)

	Please stroke out any approved Biohazards to be removed below	Write additional Biohazards for approval below. *
Approved Microorganisms	E.coli, S.corensiae	
Approved Cells	Human (established), Rodent (established), insect (established)	
Approved Use of Human Source Material		
Approved GMO	HPV (Hela), stem cell lines (Derivative and embryonic)	Adenovirus Rtt-2 promoter LB322. LB335 LB124
Approved use of Animals		
Approved Toxin(s)		

* *PLEASE ATTACH A MATERIAL SAFETY DATA SHEET OR EQUIVALENT FOR NEW BIOHAZARDS.*
** *PLEASE ATTACH A BRIEF DESCRIPTION OF THE WORK THAT EXPLAINS THE BIOHAZARDS USED AND HOW THEY WILL BE USED.*

Classification: 2

Date of last Biohazardous Agents Registry Form: Dec 16, 2006

Signature of Permit Holder:

BioSafety Officer(s):

Chair,Biohazards Subcommittee:

Caroline Schild Poulter March 2, 2009

Plasmids ordered from Addgene

LB322, LB335, LB124

These plasmids will be transfected into mammalian cells. Cells will be harvested and extracts will be prepared 24h and 48h following transfection. The activity of the reporter gene that these plasmids contain will then be monitored using a luciferase assay.
These plasmids are reporter plasmid that are for transient transfection only and will not modify the cells that they are introduced into. They will only monitor the activity of the cells under selected conditions.

addgene

Login | New User

Search for Plasmids: Go

Home Deposit Plasmids Request Plasmids Plasmid Tools About Addgene

Information Browse Search Pricing FAQ

Browse > Linda Boxer > Heckman et al > LB335 (Bcl-2 from ATG to -1281)

Print Friendly Email

Add to Cart

Price: $65.00

Plasmid Cart

Recently Viewed

Plasmid 15382: LB335 (Bcl-2 from ATG to -1281)

Gene/insert name:	B-cell lymphoma/leukemia-2
Alternative names:	Bcl-2
Insert size (bp):	1273
Gene/insert aliases:	BCL2, Bcl-2
Species of gene(s):	H. sapiens (human)
Mutations/modifications:	Bcl-2 fragment from ATG to -1281 with P2
Fusion proteins or tags:	Luciferase
Terminal:	C terminal on backbone
Vector backbone:	pBluescript II KS(+) (Search Vector Database)
Type of vector:	Bacterial expression,Luciferase
Backbone size (bp):	6000
Cloning site 5':	EagI
Site destroyed during cloning?:	No
Cloning site 3':	HindIII
Site destroyed during cloning?:	No
5' Sequencing primer:	T3 (List of Sequencing Primers)
3' Sequencing primer:	T7
Bacteria resistance:	Ampicillin
High or low copy:	Don't Know
Grow in standard E. coli @ 37C:	Yes
Sequence:	View sequence
Author's Map:	View map
Plasmid Provided In:	DH5a
Principal Investigator:	Linda Boxer
Terms and Licenses:	MTA

Plasmid Links

- Author's map
- Sequence

Related Plasmids

- From this article
- BCL2 plasmids
- Linda Boxer Lab Plasmids

Other Links

- NCBI: BCL2
- BCL2 antibodies

This is commonly requested with

- LB322 (Bcl- 2 from ATG to -3934)
- LB124 (Bcl- 2 from -1287 to -3934)

Addgene has sequenced a portion of this plasmid for verification. Click here for the sequencing result

Click on map to enlarge



Article: A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells.
Heckman CA et al. (J Biol Chem. 2000 Mar 3; 275(9):6499-508. Pubmed)

Please acknowledge the principal investigator and cite this article if you use this plasmid in a publication.

Also, please include the text "Addgene plasmid 15382" in your Materials and Methods section. This information allows Addgene to create a link from the plasmid page to your publication.

addgene

Login | New User

Search for Plasmids: Go

Browse | Deposit Plasmids | Request Plasmids | Plasmid Tools | About Addgene

Information | Browse | Search | Pricing | FAQ

Plasmid Cart

Recently Viewed

Browse > Linda Boxer > Wilson et al > LB124 (Bcl-2 from -1287 to -3934)

Print Friendly Email

Add to Cart

Price: $65.00

Plasmid 15240: LB124 (Bcl-2 from -1287 to -3934)

Gene/protein name:	B-cell lymphoma/leukemia-2
Alternative names:	Bcl-2
Insert size (bp):	2647
Gene/protein aliases:	BCL2, Bcl-2
Species of origin(s):	H. sapiens (human)
Promoter mutations/Notes:	Bcl-2 fragment from -1287 to -3934 with P1
Fusion proteins or tags:	Luciferase
Terminal:	C terminal on backbone
Vector backbone:	pBSKS+ (Search Vector Database)
Type of vector:	Luciferase,Bacterial expression
Backbone size (bp):	5553
Cloning site 5':	Pst 1
Site destroyed during cloning:	No
Cloning site 3':	Pst 1
Site destroyed during cloning:	No
5' Sequencing primer:	T7 (List of Sequencing Primers)
3' Sequencing primer:	T3
Bacterial resistance:	Ampicillin
High or low copy:	Don't Know
Gene is toxic/unstable in E. coli @ 37C:	Yes
Sequence:	View sequence
Addgene's Map:	View map
Plasmid Provided in:	DH5a
Principal Investigator:	Linda Boxer
Terms and Licenses:	MTA

Plasmid Links

- Author's map
- Sequence
- Related Plasmids
- From this article
- BCL2 plasmids
- Linda Boxer Lab Plasmids

Other Links

- NCBI: BCL2
- BCL2 antibodies

This is commonly sequenced with:

- LB335 (Bcl- 2 from ATG to -1281)
- LB322 (Bcl- 2 from ATG to -3934)

Addgene has sequenced a portion of this plasmid for verification. Click here for the sequencing result

Click on map to enlarge



Article: Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Wilson BE et al. (Mol Cell Biol. 1996 Oct; 16(10):5546-56. Pubmed)

Please acknowledge the principal investigator and cite this article if you use this plasmid in a publication.

Also, please include the text "Addgene plasmid 15240" in your Materials and Methods section. This information allows Addgene to create a link from the plasmid page to your publication.

addgene

Login | New User

Search for Plasmids: Go

Home Deposit Plasmids Request Plasmids Plasmid Tools About Addgene

Information Browse Search Pricing FAQ

Plasmid Cart

Browse > Linda Boxer > Heckman et al > LB322 (Bcl-2 from ATG to -3934)

Print Friendly Email

Add to Cart

Price: $65.00

Recently Viewed

Plasmid 15381: LB322 (Bcl-2 from ATG to -3934)

Gene/insert name:	B-cell lymphoma/leukemia-2
Alternative names:	Bcl-2
Insert size (bp):	3926
Gene/insert aliases:	BCL2, Bcl-2
Species of gene(s):	H. sapiens (human)
Mutations/modifications:	Bcl-2 fragment from ATG to -3934 with both P1 and P2
Fusion proteins or tags:	Luciferase
Terminal:	C terminal on backbone
Vector backbone:	pBluescript II KS(+) (Search Vector Database)
Type of vector:	Bacterial expression,Luciferase
Bacterial selection:	6000
Cloning site 5':	BamHI
Site destroyed during cloning:	No
Cloning site 3':	HindIII
Site destroyed during cloning:	No
5' Sequencing primer:	T3 (List of Sequencing Primers)
3' Sequencing primer:	T7
Bacterial resistance:	Ampicillin
High or low copy:	Don't Know
Grow at standard E. coli 37C:	Yes
Sequence:	View sequence
Author's Map:	View map
Plasmid Provided In:	DH5a
Principal Investigator:	Linda Boxer
Terms and Licenses:	MTA

Addgene has sequenced a portion of this plasmid for verification. Click here for the sequencing result

Click on map to enlarge

Plasmid Data
- Author's map
- Sequence
- Related Plasmids
- From this article
- BCL2 plasmids
- Linda Boxer Lab Plasmids

Gene Links
- NCBI: BCL2
- BCL2 antibodies

This is commonly requested with:
- LB335 (Bcl-2 from ATG to -1281)
- LB124 (Bcl-2 from -1287 to -3934)



Article: A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells.
Heckman CA et al. (J Biol Chem. 2000 Mar 3; 275(9):6499-508. Pubmed)

Please acknowledge the principal investigator and cite this article if you use this plasmid in a publication.

Also, please include the text "Addgene plasmid 15381" in your Materials and Methods section. This information allows Addgene to create a link from the plasmid page to your publication.

2006-18

robarts RESEARCH

BIOHAZARDOUS AGENTS REGISTRY FORM

Reviewed by Biosafety Subcommittee: February 2006

This form must be completed by each Principal Investigator when completing a grant application or grant renewal to be administered by the Robarts Research Institute, if the use of biohazardous and/or infectious agents is proposed. For any proposed animal work involving the use of biohazardous agents or animals carrying zoonotic agents infectious to humans, this form must also be completed.

COMPLETED FORMS ARE TO BE RETURNED TO BIOSAFETY SUBCOMMITTEE CHAIR, ROOM 3-34.1.

If there are any changes to the information on these forms (excluding grant title and funding agencies) a new form must be completed and sent to the Biosafety Subcommittee Chair BEFORE implementation of these changes can occur.

If multi-team grants are being applied for, each individual investigator of the team must submit a Biohazardous Agents Registry Form to the Biosafety Subcommittee Chair.

Containment Levels will be required in accordance with Health Canada (HC), Laboratory Biosafety Guidelines, 3rd edition 2004, or Canadian Food Inspection Agency (CFIA), Containment Standards for Veterinary Facilities, 1st edition 1996.

For questions regarding this form, please contact Biosafety Subcommittee Chair at ext. 34125.

1.0 Contact Information

PRINCIPAL INVESTIGATOR: Caroline Schild Poulter

SIGNATURE: C. Schild-Poulter

DATE: Nov 3, 2006

DEPARTMENT: Cell Biology

ADDRESS: PO Box 5015, 100 Perth Drive London

TELEPHONE: 663-5777 ext 34164

EMAIL: cschild.poulter@robarts.ca

Location of experimental work to be carried out:

Building(s): Robarts Research

Room(s): J. Allyn Taylor Centre 6

**For work being performed at Institutions affiliated with the Robarts Research Institute, the Safety Officer for the Institution where experiments will take place must sign the form prior to it being sent to Robarts Research Institute, Biosafety Subcommittee Chair. See Section 13.0, Approvals*

GRANT TITLE(S): Molecular mechanisms of transcription factor Oct-1 function in response to DNA damage.

ATTACH A BRIEF DESCRIPTION OF YOUR WORK, SUCH AS THE RESEARCH GRANT SUMMARY(S) EXPLAINING THE BIOHAZARD(S) USED.

FUNDING AGENCY/AGENCIES: NCIC (Submitted)

Anticipated Grant End Date: 7/2010

Names of all personnel working under Principal Investigator's supervision in this location:

Dawn Bryce

Note : A list of human pathogens categorized according to Risk Group can be obtained by calling the Office of Laboratory Security directly at (613) 957-1779 or accessing their Web site : http://www.phac-aspc.gc.ca/ols-bsl/index.html

2.0 Microorganisms

2.1 Does your work involve the use of microorganisms? **YES** ☒ **NO** ○
If **NO**, please proceed to Section **3.0**

2.2 Please complete the table below:

Name of Microorganism	Is microorganism a known human pathogen? **YES/NO**	Is microorganism a known animal pathogen? **YES/NO**	Is microorganism a known zoonotic agent? **YES/NO**	Maximum quantity to be cultured at one time?	Health Canada or CFIA Containment Level (select one)
E. coli	yes	yes	yes	2 Pt	10 20 ~~20~~ 30
S. cerevisiae	yes	yes	yes	2 Pt	10 20 ~~20~~ 30
					10 20 30

3.0 Cell Culture

3.1 Does your work involve the use of cell cultures? YES ⊗ NO ○
If **NO**, please proceed to Section **4.0**.

3.2 Please indicate in the table below the type of cells that will be grown in culture.

Cell Type	Is this cell type used in your work? YES / NO	Established or Primary *	Supplier of Primary Cell Culture Tissue
Human	Yes	established	
Rodent	yes	established	
Non-human primate	NO		
Other (specify)	Insect (established)		

* i.e. derived from fresh tissue

3.3 Complete the following table.

Specific Cell Line	Source / Supplier	HC or CFIA Containment Level (select one)
MCF7	ATCC	1 ○ 2 ⊗ 3 ○
Phoenix (293T-derivative)	Non commercial	1 ○ 2 ⊗ 3 ○
mouse embryonic fibroblast	"	1 ○ 2 ⊗ 3 ○
(new) Hela (human)	ATCC CCL-2	1 ○ 2 ⊗ 3 ○

4.0 Use of Human Source Materials

4.1 Does your work involve the use of human source materials? YES ○ NO ⊗
If **NO**, please proceed to Section **5.0**

4.2 Indicate in the table below the Human Source Material to be used.

Human Source Material	Specify Source, or Not Applicable (NA)	Is Human Source Material known to be infected with an infectious agent? YES/NO	Name of Infectious Agent	HC or CFIA Containment Level (select one)
Human Blood (whole) or other Body Fluid				1 ○ 2 ○ 3 ○
Human Blood (fraction) or other Body Fluid				1 ○ 2 ○ 3 ○
Human Organs (unpreserved)				1 ○ 2 ○ 3 ○
Human Tissues (unpreserved)				1 ○ 2 ○ 3 ○

5.0 Genetically Modified Organisms and Cell lines

5.1 Will genetic modifications be made to the organism, virus or cell line? YES ☒ NO ○
If **NO**, please proceed to Section **6.0**

5.2 Will genetic sequences from any of the following be involved?

- HIV YES ○ NO ☒

If **YES**, specify: _____

- HTLV 1 or 2 YES ○ NO ☒

If **YES**, specify: _____

- Other human or animal pathogen and/or their toxins YES ○ NO ☒

If **YES**, specify: _____

5.2 Will intact genetic sequences be used from:

- SV 40 Large T antigen YES ☒ NO ○
- Adeno E1A YES ○ NO ☒
- Known or suspected oncogenes YES ☒ NO ☒

If **YES**, specify: HPV(Hela)

5.4 Will a live vector(s) (viral or bacterial) be used for gene transduction? YES ☒ NO ○

If **YES**, name vector: Murine Stem Cell Virus (Derivative of Embryonic Stem Cell virus

5.5 List specific vector(s) to be used: PMSCV what envelope + amphotropic for what purposes not mentioned in summary.

5.6 Will vector be replication defective? YES ☒ NO ○

5.7 Will vector be infectious to humans or animals? YES ☒ NO ○

5.8 Will this be expected to increase the Containment Level required? YES ○ NO ☒

6.0 Human Gene Therapy Trials

6.1 Will human clinical trials using the vector(s) in 5.5 be conducted? YES ○ NO ☒
If **NO**, please proceed to Section **7.0**
If YES, attach a full description of the make-up of the virus.

6.2 Will vector be able to replicate in the host? YES ○ NO ○

6.3 How will the vector be administered? _____

6.4 Please give the Health Care Facility where the clinical trial will be conducted:

_____

6.5 Has human ethics approval been obtained? YES ○ NO ○

Approval # _____

7.0 Animal Experiments

7.1 Will any of the agents listed be used in live animals? YES O NO ⊗
If **NO**, please proceed to section 8.0

7.2 Name of animal species to be used: _____

7.3 AUS protocol # _____

7.4 If using murine cell lines, have they been tested for murine pathogens? YES O NO O

8.0 Use of Animal species with Zoonotic Hazards

8.1 Will any of the following animals or their organs, tissues, lavages or other bodily fluids including blood be used?

- Pound source dogs YES O NO ⊗
- Pound source cats YES O NO ⊗
- Sheep or goats YES O NO ⊗
- Non- Human Primates YES O NO ⊗

If **YES** specify species _____

- Wild caught animals YES O NO ⊗

If **YES** specify species _____

9.0 Biological Toxins

9.1 Will toxins of biological origin be used? YES O NO ⊗
If **NO**, please proceed to Section **10.0**
If **YES**, please name the toxin _____

9.2 What is the LD_{50} (specify species) of the toxin? _____

10.0 Import Requirements

10.1 Will the agent be imported? YES O NO ⊗
If **NO**, please proceed to Section **11.0**
If **YES**, country of origin _____

10.2 Has an Import Permit been obtained from HC for human pathogens? YES O NO ⊗

10.3 Has an import permit been obtained from CFIA for animal pathogens? YES O NO ⊗

10.4 Has the import permit been sent to Biosafety Subcommittee Chair? YES O NO ⊗

If **YES**, Permit # _____

11.0 Training Requirements for Personnel Named on Form

All personnel named in section **1.0** of this form who will be using any of the above named agents are required to attend the following training courses given by OH&S.

- Biosafety
- Laboratory and Environmental/Waste Management Safety
- WHMIS

As the Principal Investigator, I have ensured that all of the personnel named on the form who will be using any of the biohazardous agents in Sections 2.0 to 10.0 have been trained as required.

SIGNATURE _____

12.0 Containment Levels

12.1 For the work described in sections **2.0** to **10.0**, select the highest HC or CFIA Containment Level required. 1O 2☒ 3O

12.2 Has the facility been certified by Biosafety Subcommittee Chair for this level of containment?

YES ☒ NO O

If **YES**, give date: Nov 16, 06 and permit number: 2006.03-CB-CSP

13.0 Approvals

Robarts Research Institute

Signature _____ Date Dec. 13, 2006

Biosafety Officer for the Institution where experiments will take place

Signature _____ Date _____

Biosafety Officer of Robarts Research Institute (if different than above)

Signature _____ Date _____

Note: This permit will be in effect from _____ to _____,

subject to annual facility re-certification.